Financial PerformanceR&D expenses were $9.3MM, higher than the estimated $8.1MM, indicating increased spending.
Strategic Focus ShiftThe company has deprioritized its oncology programs, which may impact its current focus and resources.
Valuation ImpactThe restructuring led to the elimination of CUE-101 from valuation, resulting in a lower price target for the company.